secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-04-04T23:59:59+00:00
Accession:  0000950170-25-051179
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Former CFO Marc Wilson transitions to consultant role through April 2026
------------------------------------------------------------------------

- Wilson resigned as employee on April 1, 2025, and entered a consulting agreement through April 1, 2026, with a possible six-month extension.
- He will receive $300 per hour for services plus reimbursement of reasonable out-of-pocket expenses.
- Outstanding equity awards continue vesting during consulting period; accelerates upon termination without cause, death, disability, or change in control.
- The agreement includes a general release of claims against the company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025051179/0000950170-25-051179-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017025051179/crnx-20250401.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-051179

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer